Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Frontiers in oncology·2026
Same author

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Blood cancer journal·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026
Same author

Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.

Haematologica·2026
Same author

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Nature medicine·2026

Related Experiment Video

Updated: Sep 19, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Multiple Myeloma Unpacked.

Francesca Gay1, Edoardo Marchetti1, Giuseppe Bertuglia1

  • 1Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health Science, University of Torino, Torino, Italy.

Hematological Oncology
|June 15, 2025
PubMed
Summary

Multiple myeloma (MM) is a plasma cell cancer. Current treatments improve survival, but new therapies are needed for relapsed/refractory cases, including CAR T-cell therapy and novel agents.

Keywords:
immunotherapiesmyelomaresponse assessmentstaging

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Experiment Videos

Last Updated: Sep 19, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Area of Science:

  • Hematologic Oncology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is a bone marrow malignancy driven by clonal plasma cells.
  • Current treatments, including proteasome inhibitors and stem cell transplantation, have improved survival.
  • Relapsed and refractory MM remain significant clinical challenges.

Purpose of the Study:

  • To review diagnostic criteria, prognostic factors, and response assessment in multiple myeloma.
  • To summarize the current therapeutic landscape for multiple myeloma.
  • To highlight emerging treatment strategies for multiple myeloma.

Main Methods:

  • Literature review of diagnostic criteria and prognostic features.
  • Analysis of current treatment modalities for multiple myeloma.
  • Overview of ongoing clinical trials and novel therapeutic agents.

Main Results:

  • Established diagnostic criteria and prognostic indicators for MM.
  • Detailed summary of standard-of-care treatments, including proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation.
  • Identification of promising novel therapies such as CAR T-cell therapy, bispecific antibodies, and Cereblon E3 Ligase Modulatory Drugs.

Conclusions:

  • Multiple myeloma treatment has advanced, significantly improving patient outcomes.
  • Despite progress, challenges persist in managing relapsed and refractory disease.
  • Emerging therapies hold promise for further improving MM management and patient survival.